<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04895436</url>
  </required_header>
  <id_info>
    <org_study_id>M20-356</org_study_id>
    <secondary_id>2021-001037-39</secondary_id>
    <nct_id>NCT04895436</nct_id>
  </id_info>
  <brief_title>Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)</brief_title>
  <official_title>A Multicenter, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Venetoclax-Obinutuzumab Retreatment in Patients With Recurring Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>F. Hoffmann-La Roche Ltd; German CLL Study Group (GCLLSG); Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The&#xD;
      purpose of this study is to assess how well venetoclax + obinutuzumab (VenG) works and how&#xD;
      safe they are in adult participants with CLL who were previously treated with VenG. Adverse&#xD;
      events and change in disease activity will be assessed.&#xD;
&#xD;
      Venetoclax is an approved drug for the treatment of CLL. Study doctors put the participants&#xD;
      in 1 of 2 groups, called treatment arms, based on when symptoms of CLL came back after&#xD;
      previous treatment with VenG. Approximately 75 adult participants with CLL who have been&#xD;
      treated with VenG will be enrolled in the study in approximately 60 sites worldwide.&#xD;
&#xD;
      Participants will receive intravenous (IV) obinutuzumab + oral venetoclax (VenG) in 28-day&#xD;
      cycles for a total of 6 cycles per cohort, followed by 6 to 18 cycles of venetoclax alone,&#xD;
      for a total treatment of 12 to 24 cycles, depending on the cohort.&#xD;
&#xD;
      There may be higher treatment burden for participants in this trial compared to their&#xD;
      standard of care. Participants will attend regular visits during the study at a hospital or&#xD;
      clinic. The effect of the treatment will be checked by medical assessments, blood tests,&#xD;
      checking for side effects and completing questionnaires.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2, 2021</start_date>
  <completion_date type="Anticipated">November 18, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR) in Cohort 1 after end of combination treatment</measure>
    <time_frame>9 months</time_frame>
    <description>Overall response rate is defined as the percentage of participants achieving a best response of partial remission (PR), nodular partial remission (nPR), complete remission with incomplete marrow recovery (CRi), or complete remission (CR). Disease assessments will be based on the 2018 International Workshop for Chronic Lymphocytic Leukemia (iwCLL) criteria for tumor response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CR rate in Cohort 1 after end of combination treatment</measure>
    <time_frame>9 months</time_frame>
    <description>CR rate is defined as the percentage of participants achieving a best response of CR or CRi</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR Rate in Cohort 1 after end of treatment</measure>
    <time_frame>15 months</time_frame>
    <description>CR rate is defined as the percentage of participants achieving a best response of CR or CRi.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR in Cohort 1 after end of treatment</measure>
    <time_frame>15 months</time_frame>
    <description>ORR is defined as the percentage of participants achieving a best response of PR, nPR, CRi, or CR. Disease assessments will be based on the 2018 iwCLL criteria for tumor response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR) in Cohort 1</measure>
    <time_frame>15 months</time_frame>
    <description>TTR is defined as the time from first dose until first response (PR or better).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) in Cohort 1</measure>
    <time_frame>15 months</time_frame>
    <description>DOR is defined as the time from first response (PR or better) until progressive disease (PD) or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Next Treatment (TTNT) for CLL in Cohort 1</measure>
    <time_frame>15 months</time_frame>
    <description>TTNT is defined as the time from first dose until first dose of a non-protocol anti-CLL therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) in Cohort 1</measure>
    <time_frame>15 months</time_frame>
    <description>PFS is defined as the time from first dose until PD or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) in Cohort 1</measure>
    <time_frame>15 months</time_frame>
    <description>OS is defined as the time from first dose until death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Undetectable Minimal Residual Disease (uMRD) rate (10^-4) in Cohort 1 after end of combination treatment</measure>
    <time_frame>9 months</time_frame>
    <description>Percentage of participants with uMRD rate, measured in peripheral blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Undetectable Minimal Residual Disease (uMRD) rate (10^-4) in Cohort 1 after end of treatment</measure>
    <time_frame>15 months</time_frame>
    <description>Percentage of participants with uMRD rate, measured in peripheral blood.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Chronic Lymphocytic Leukemia (CLL)</condition>
  <arm_group>
    <arm_group_label>Cohort 1 - venetoclax + obinutuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive venetoclax + obinutuzumab for six 28-day cycles followed by venetoclax for six 28-day cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - venetoclax + obinutuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive venetoclax + obinutuzumab for six 28-day cycles followed by venetoclax for eighteen 28-day cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Oral tablet</description>
    <arm_group_label>Cohort 1 - venetoclax + obinutuzumab</arm_group_label>
    <arm_group_label>Cohort 2 - venetoclax + obinutuzumab</arm_group_label>
    <other_name>Venclexta</other_name>
    <other_name>ABT-199</other_name>
    <other_name>GDC-0199</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab</intervention_name>
    <description>Intravenous (IV) infusion</description>
    <arm_group_label>Cohort 1 - venetoclax + obinutuzumab</arm_group_label>
    <arm_group_label>Cohort 2 - venetoclax + obinutuzumab</arm_group_label>
    <other_name>GA101</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented diagnosis of chronic lymphocytic leukemia (CLL) that requires treatment for&#xD;
             CLL according to International Workshop for Chronic Lymphocytic Leukemia (iwCLL) 2018&#xD;
             criteria.&#xD;
&#xD;
          -  Previously completed venetoclax + obinutuzumab (VenG) regimen as a fixed duration&#xD;
             first-line (1L) therapy and achieved documented response, defined as complete&#xD;
             remission, complete remission with incomplete marrow recovery, partial remission, or&#xD;
             nodular partial remission.&#xD;
&#xD;
          -  More than 24 months (Cohort 1) or 12-24 months (Cohort 2) have elapsed between last&#xD;
             dose of venetoclax and disease progression after completion of 1L VenG treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Received intervening treatment for CLL after previous treatment with VenG.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine /ID# 230060</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-2927</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago /ID# 230178</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Ins, Carolina Me /ID# 230193</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre /ID# 229845</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Koeln /ID# 230296</name>
      <address>
        <city>KÃ¶ln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Haematologie - Onkologie BAG /ID# 230168</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Princesa /ID# 229665</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.rxabbvie.com/</url>
    <description>Related info</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2021</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Lymphocytic Leukemia (CLL)</keyword>
  <keyword>Venetoclax</keyword>
  <keyword>ABT-199</keyword>
  <keyword>Venclexta</keyword>
  <keyword>GDC-0199</keyword>
  <keyword>Obinutuzumab</keyword>
  <keyword>GA101</keyword>
  <keyword>Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
    <mesh_term>Obinutuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

